Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double Blind Placebo-controlled, Long-term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis

NCT00812799 is registered in ClinicalTrials.gov with Artu Biologicals as lead sponsor.

NCT NCT00812799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00812799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double Blind Placebo-controlled, Long-term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis
Lead sponsor
Artu Biologicals
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2008
Completion date
December 31, 2011
Enrollment
374 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinoconjunctivitis